Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian
pharmaceutical company Aché Laboratórios

EQS-News: Marinomed Biotech AG / Key word(s): Alliance
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian
pharmaceutical company Aché Laboratórios

25.04.2024 / 07:45 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian
pharmaceutical company Aché Laboratórios

  * Marinomed will apply the Marinosolv solubilization technology to improve
    target compounds with the goal of developing products with
    differentiated pharmacological profiles

  * The project covers the proof-of-concept evaluation and future
    development of selected products with exclusivity rights for Aché in
    Latin America

  * Second long-term partnership for Marinomed's Solv4U business area to
    generate royalites after successful market entry

Korneuburg, Austria, 25 April 2024 - Marinomed Biotech AG (VSE:MARI)
announces the establishment of an R&D collaboration under its Solv4U
platform with Aché Laboratórios Farmaceuticos S.A., one of the largest and
most innovative pharmaceutical companies in Brazil. Aché is known for its
leadership in prescription medicines, and its commitment to developing
innovative solutions for unmet medical needs. Through its Solv4U partnership
program, Marinomed offers its proprietary Marinosolv solubilization
technology to customers from pharma and biotech to address solubility and
bioavailability issues and support the formulation development of active
pharmaceutical ingredients (APIs). The scope of the collaboration is to
assess the Marinosolv technology in selected molecules with the aim of
achieving products with improved pharmacological profiles, enhanced
solubility, and lower dosages. Aché will have exclusive rights to apply the
Marinosolv technology to the targeted compounds, which are intended to be
further developed and marketed as pharmaceutical products under Aché's
trademarks in the LATAM region. After successful market entry, Marinomed
will benefit from royalties on sales of the products in the Latin American
growth market. The agreement also includes provisions for both parties to
exploit the potential of these products in ex-LATAM territories, based on
the successful completion of the R&D feasibility stage.

Cornelia Siegl, Head of Solv4U, commented: "We are excited to embark on this
journey with Aché and look forward to the collaboration on this Solv4U
project with such an innovative partner. The conclusion of a further
long-term Solv4U partnership shows that low drug solubility and
bioavailability are still one of the biggest hurdles in drug development and
that innovative solutions like ours are urgently needed. The Marinosolv
technology has proven to be successfully applicable to a wide range of
pharmaceutical compounds not only in our own product development but also in
various partner projects."

Andreas Grassauer, CEO of Marinomed, added: "Following the Solv4U
partnership with our Shanghai-based partner SPH Sine Pharmaceuticals last
year, the cooperation with Aché Laboratórios is another important milestone
in Marinosolv's success story. We look forward to working closely with Aché
for the next years in the dynamic growth market of Latin America. Technology
partnerships like that accelerate the transition from research to commercial
application. We are excited to further expand our Solv4U business in the
future and to improve the efficacy of active pharmaceutical compounds with
our innovative Marinosolv technology."

Hatylas Azevedo, R&D Director of Aché, said: "We're excited to collaborate
with Marinomed to investigate the potential of the Marinosolv technology on
increasing pharmacokinetic and pharmacodynamic properties of first-line
treatments for prevalent diseases. Aché's experience in the R&D and
commercialization of innovative medicines will teamwork with Marinomed's
know-how and cutting-edge technology for developing differentiated products
that address important unmet medical needs."

About Aché Laboratórios Farmaceuticos S.A.

Aché Laboratórios Farmaceuticos S.A. is a reputable Brazilian pharmaceutical
company established 57 years ago. Renowned in the fields of prescription and
specialty medicines, it stands as one of Brazil's largest and most
innovative pharmaceutical companies. Operating from five industrial
facilities, Aché manufactures a wide array of pharmaceuticals, including
solids, liquids, semi-solids, parenteral drugs, antibiotics, and
contraceptives. The company boasts a workforce of around 5,000 employees and
maintains a portfolio comprising over 300 branded products spanning various
therapeutic domains, being the leader of Respiratory care in Brazil.
Recognized by its innovation and quality, Aché has been recognized as the
most innovative company in the pharmaceutical sector. Nearly 350 personnel
are dedicated to R&D activities such as drug discovery, pharmaceutical
sciences, preclinical and clinical development, alongside a business
development unit focused on fostering partnerships. In recent years, Aché
has introduced numerous groundbreaking products and forged global
collaborations with prominent biotech and pharmaceutical firms, aiming to
pioneer novel compounds, fixed-dose combinations and innovative dosage forms
and technologies for addressing diseases with substantial unmet medical
needs.

About Marinosolv®:

Marinosolv® is an innovative technology platform that enables the
solubilization and enhances the bioavailability of small molecules and
peptides that are hardly soluble in aqueous formulations. Consequently, new
treatments of a multitude of diseases can be envisaged. The use of the
Marinosolv® technology can facilitate efficient drug delivery with a low
systemic off-target activity. Existing drugs and off-patent active
ingredients can be improved and re-patented as part of new formulations
using Marinosolv®. Under the brand Solv4U, Marinomed provides Marinosolv®
formulation development in technology partnerships for active ingredients at
all stages of drug discovery and for lifecycle extension. For more
information on Marinosolv® or Solv4U, please visit https://www.solv4u.com.
Scientific publications on Marinosolv® can be accessed in the "Immunology"
tabs at https://www.marinomed.com/en/news/scientific-publications.

About Marinomed Biotech AG

Marinomed Biotech AG is an Austrian, science-based biotech company with a
growing development pipeline and globally marketed therapeutics. The Company
develops innovative patent-protected products in the therapeutic areas
immunology and virology based on the platform Marinosolv® and the
virus-blocking activity of Carragelose®. The Marinosolv® technology improves
the solubility and bioavailability of hardly soluble compounds and is used
to develop new therapeutics for autoreactive immune disorders. The virology
segment includes Carragelose®-based over-the-counter (OTC) products to
prevent and treat respiratory viral infections that are partnered in more
than 40 countries. The Company is headquartered in Korneuburg, Austria, and
is listed on the prime market of the Vienna Stock Exchange (VSE:MARI). For
further information, please visit: https://www.marinomed.com.

For further inquiries contact:

            Marinomed Biotech AG           International Media Contact
          PR & IR: Lucia Ziegler    Metrum Communications: Eva Ruppnig
           T: +43 2262 90300 158                    T: +43 664 4065744
     E-Mail: (1)pr@marinomed.com        E-Mail: (1)marinomed@metrum.at
     E-Mail: (2)ir@marinomed.com

                                         1. mailto:marinomed@metrum.at
      1. mailto:pr@marinomed.com
      2. mailto:ir@marinomed.com

Disclaimer

This press release contains forward-looking statements, which are based on
current views, expectations and projections of the management of Marinomed
Biotech AG about future events. These forward-looking statements are subject
to risks, uncertainties and assumptions that could cause actual results,
performance or events to differ materially from those described in, or
expressed or implied by, such statements. The current views, expectations
and projections of the management of Marinomed Biotech AG may be identified
by the context of such statements or words such as "anticipate," "believe",
"estimate", "expect", "intend", "plan", "project" and "target".
Forward-looking statements are only valid as of the date they are made and
Marinomed Biotech AG does not assume any obligation to update, review or
revise any forward-looking statements contained in this press release
whether as a result of new information, future developments or otherwise.
Marinomed, Marinosolv® and Carragelose® are registered trademarks of
Marinomed Biotech AG. These trademarks may be owned or licensed in select
locations only.


---------------------------------------------------------------------------

25.04.2024 CET/CEST This Corporate News was distributed by EQS Group AG.
www.eqs.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Marinomed Biotech AG
                   Hovengasse 25
                   2100 Korneuburg
                   Austria
   Phone:          +43 2262 90300
   E-mail:         office@marinomed.com
   Internet:       www.marinomed.com
   ISIN:           ATMARINOMED6
   WKN:            A2N9MM
   Listed:         Regulated Unofficial Market in Berlin, Dusseldorf,
                   Frankfurt, Munich, Stuttgart, Tradegate Exchange;
                   Vienna Stock Exchange (Official Market)
   EQS News ID:    1888693

End of News EQS News Service
---------------------------------------------------------------------------

1888693 25.04.2024 CET/CEST